Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premature infants and maternal pertussis immunization: benefit of second-trimester vaccination
2018-002976-41Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of acellular pertussis vaccine in pertussis (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Infant serum anti-PT IgG at 2 months. Started Jul 2019; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on 2018-002976-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002976-41.